CDA | Evidence Driven
CDA | Evidence Driven

Nexavar for Metastatic Progressive Differentiated Thyroid Carcinoma - Details

Details

Files
Generic Name:
Sorafenib
Project Status:
Complete
Therapeutic Area:
Metastatic Progressive Differentiated Thyroid Carcinoma (DTC)
Manufacturer:
Bayer Inc.
Brand Name:
Nexavar
Project Line:
Reimbursement Review
Project Number:
PC0049-000
Performance Metric:
N/A — Predated performance metrics
Strength:
200 mg tablet
Tumour Type:
Endocrine
Indications:
Metastatic Progressive Differentiated Thyroid Carcinoma (DTC)
Funding Request:
Treatment of patients with locally advanced or metastatic, progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine
Sponsor:
Bayer Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting (target date):
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
Clarification:
Due to the number of items for deliberation, the pERC meeting was conducted over two days. Unable to reach quorum for either day around the target reconsideration meeting date of June 18, 2015, pERC held deliberations for all reconsideration items, including sorafenib, on July 2, 2015.
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Sorafenib (Nexavar) for DTC – Final Recommendation Final Recommendation July 16, 2015 View PDF
Sorafenib (Nexavar) DTC - Final Clinical Guidance Report Guidance Reports July 16, 2015 View PDF
Sorafenib (Nexavar) DTC - Final Economic Guidance Report Guidance Reports July 16, 2015 View PDF
Sorafenib (Nexavar) DTC - Initial pERC Recommendation Initial Recommendation April 30, 2015 View PDF
Sorafenib (Nexavar) for DTC – PAG Feedback on Initial Recommendation Feedback July 16, 2015 View PDF
Sorafenib (Nexavar) for DTC – Manufacturer Feedback on Initial Recommendation Feedback July 16, 2015 View PDF
Sorafenib (Nexavar) for DTC – Patient Advocacy Group (TCC) Feedback on Initial Recommendation Feedback July 16, 2015 View PDF
Sorafenib (Nexavar) for DTC – Patient Advocacy Group (TCC) COI Declarations COI Declarations July 16, 2015 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : September 29, 2015